Histopathological and serological progression of experimental Staphylococcus aureus arthritis.
In a newly developed mouse model of Staphylococcus aureus arthritis the kinetics of joint destruction and serological manifestations as well as the clinical course of arthritis and osteitis were studied. Almost all mice developed histopathological signs of arthritis upon a single intravenous injection of 10(7) S. aureus LS-1 cells. There was rapid joint destruction, with synovial hypertrophy already visible, within 24 h after injection of the bacteria. Cartilage and/or bone erosions were seen in a majority of the mice within 72 h. Extra-articular manifestations, especially signs of bone infection, were also found soon after inoculation of the bacteria. Tail osteitis was frequent (50% of the mice) but appeared later than arthritis. Polymorphonuclear cells prevailed in the early joint lesions and were also common in the extra-articular manifestations. Within 3 days, mononuclear cells were also seen in the inflamed synovium, gaining a dominant position 3 weeks after the start of the disease. Serum interleukin-6 levels were already increased within 6 h after bacterial injection and remained elevated throughout the course of arthritis. Serum tumor necrosis factor levels were increased within 24 h. There was a tremendous induction of immunoglobulin production, especially of the immunoglobulin G1 isotype. This was paralleled by the production of specific antibodies to S. aureus (cell walls and toxin), as well as autoantibodies (rheumatoid factors and anti-single-stranded DNA antibodies), all predominantly of the immunoglobulin G isotype. The type and magnitude of the immunoglobulin G response together with the elevated interleukin-6 levels speak in favor of both antigen-specific and polyclonal B-cell activation during S. aureus arthritis. This study points out important similarities between our new model of S. aureus arthritis and human S. aureus arthritis. This resemblance will enable controlled studies of pathogenetic mechanisms of septic arthritis as well as therapeutic and prophylactic approaches.
Bremell
T
T
Department of Rheumatology, University of Göteborg, Sweden.
Abdelnour
A
A
Tarkowski
A
A
D000818:Animals; D000974:Antibodies, Antinuclear / Q000096:biosynthesis; D016918:Arthritis, Reactive / Q000276:immunology* / Q000473:pathology*; D001425:Bacterial Outer Membrane Proteins / Q000096:biosynthesis; D001427:Bacterial Toxins; D004277:DNA, Single-Stranded / Q000276:immunology; D004195:Disease Models, Animal; D004768:Enterotoxins / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D051379:Mice; D010000:Osteitis / Q000276:immunology / Q000473:pathology; D012217:Rheumatoid Factor / Q000097:blood; D013203:Staphylococcal Infections; D018089:Superantigens; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000974:Antibodies, Antinuclear; D001425:Bacterial Outer Membrane Proteins; D001427:Bacterial Toxins; D004277:DNA, Single-Stranded; D004768:Enterotoxins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D015850:Interleukin-6; D018089:Superantigens; D014409:Tumor Necrosis Factor-alpha; C030107:enterotoxin F, Staphylococcal; D012217:Rheumatoid Factor